Scholarlink

<p>Chronic chikungunya disease is caused by the mosquito-borne chikungunya virus (CHIKV) induced by viral persistence in target tissues. To investigate the risk of viral persistence of the approved live-attenuated vaccine IXCHIQ<sup>®</sup> (VLA1553), cynomolgus macaques received a 100-fold higher dose than the approved dose for IXCHIQ<sup>®</sup> or wild-type CHIKV. In VLA1553-treated NHPs, fever was transient, coinciding with peak viremia, with no significant virus detected in tissues except for immune organs. WT CHIKV-treated NHPs developed fever persisting for several days with higher peak viremias, and virus was consistently detected in tissues at higher levels than in VLA1553-treated animals. Additionally, WT CHIKV-treated NHPs showed more CHIKV in saliva and vaginal fluid, lymphocytopenia, increased liver enzymes and plasma prostaglandin E<sub>2</sub>, and higher expression of pro-inflammatory cytokines and chemokines associated with WT CHIKV disease than VLA1553-treated animals. This study demonstrated attenuation of vaccine strain VLA1553, with no critical observations in non-human primates (NHPs) following administration of a high dose.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Limited tissue persistence confirms attenuation of live-attenuated chikungunya vaccine VLA1553 in non-human primates

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月23日

查看全文
  • Pierre Roques,
  • Andrea Fritzer,
  • Nathalie Dereuddre-Bosquet,
  • Laetitia Bossevot,
  • Quentin Pascal,
  • Roger Le Grand,
  • Urban Lundberg,
  • Andreas Meinke

摘要

Chronic chikungunya disease is caused by the mosquito-borne chikungunya virus (CHIKV) induced by viral persistence in target tissues. To investigate the risk of viral persistence of the approved live-attenuated vaccine IXCHIQ® (VLA1553), cynomolgus macaques received a 100-fold higher dose than the approved dose for IXCHIQ® or wild-type CHIKV. In VLA1553-treated NHPs, fever was transient, coinciding with peak viremia, with no significant virus detected in tissues except for immune organs. WT CHIKV-treated NHPs developed fever persisting for several days with higher peak viremias, and virus was consistently detected in tissues at higher levels than in VLA1553-treated animals. Additionally, WT CHIKV-treated NHPs showed more CHIKV in saliva and vaginal fluid, lymphocytopenia, increased liver enzymes and plasma prostaglandin E2, and higher expression of pro-inflammatory cytokines and chemokines associated with WT CHIKV disease than VLA1553-treated animals. This study demonstrated attenuation of vaccine strain VLA1553, with no critical observations in non-human primates (NHPs) following administration of a high dose.